Albert Isidro-Llobet
Overview
Explore the profile of Albert Isidro-Llobet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kekessie I, Wegner K, Martinez I, Kopach M, White T, Tom J, et al.
J Org Chem
. 2024 Mar;
89(7):4261-4282.
PMID: 38508870
Small molecule therapeutics represent the majority of the FDA-approved drugs. Yet, many attractive targets are poorly tractable by small molecules, generating a need for new therapeutic modalities. Due to their...
2.
Roth S, Kocaturk N, Sathyamurthi P, Carton B, Watt M, Macartney T, et al.
Cell Chem Biol
. 2023 Aug;
30(10):1261-1276.e7.
PMID: 37591251
Targeted protein degradation (TPD), induced by enforcing target proximity to an E3 ubiquitin ligase using small molecules has become an important drug discovery approach for targeting previously undruggable disease-causing proteins....
3.
Characterisation of IL-23 receptor antagonists and disease relevant mutants using fluorescent probes
Lay C, Isidro-Llobet A, Kilpatrick L, Craggs P, Hill S
Nat Commun
. 2023 May;
14(1):2882.
PMID: 37208328
Association of single nucleotide polymorphisms in the IL-23 receptor with several auto-inflammatory diseases, led to the heterodimeric receptor and its cytokine-ligand IL-23, becoming important drug targets. Successful antibody-based therapies directed...
4.
Venneti N, Samala G, Morsy R, Mendoza L, Isidro-Llobet A, Tom J, et al.
J Am Chem Soc
. 2023 Jan;
145(2):1053-1061.
PMID: 36602440
Peptides are steadily gaining importance as pharmaceutical targets, and efficient, green methods for their preparation are critically needed. A key deficiency in the synthetic toolbox is the lack of an...
5.
Bargh J, Walsh S, Isidro-Llobet A, Omarjee S, Carroll J, Spring D
Chem Sci
. 2021 Jun;
11(9):2375-2380.
PMID: 34084399
Antibody-drug conjugates (ADCs) are a class of targeted drug delivery agents combining the cell-selectivity of monoclonal antibodies (mAbs) and the cytotoxicity of small molecules. These two components are joined by...
6.
Bargh J, Walsh S, Ashman N, Isidro-Llobet A, Carroll J, Spring D
Chem Commun (Camb)
. 2021 Mar;
57(28):3457-3460.
PMID: 33687404
A novel enzyme cleavable linker for antibody-drug conjugates is reported. The 3-O-sulfo-β-galactose linker is cleaved sequentially by two lysosomal enzymes - arylsulfatase A and β-galactosidase - to release the payload...
7.
Vantourout J, Mason A, Yuen J, Simpson G, Evindar G, Kuai L, et al.
Bioconjug Chem
. 2021 Feb;
32(2):279-289.
PMID: 33523652
Reducing the required frequence of drug dosing can improve the adherence of patients to chronic treatments. Hence, drugs with longer half-lives are highly desirable. One of the most promising approaches...
8.
Walsh S, Bargh J, Dannheim F, Hanby A, Seki H, Counsell A, et al.
Chem Soc Rev
. 2020 Dec;
50(2):1305-1353.
PMID: 33290462
Antibody-drug conjugates (ADCs) harness the highly specific targeting capabilities of an antibody to deliver a cytotoxic payload to specific cell types. They have garnered widespread interest in drug discovery, particularly...
9.
Grimes J, Desai S, Charter N, Lodge J, Moita Santos R, Isidro-Llobet A, et al.
Pharmacol Res Perspect
. 2019 Dec;
7(6):e00547.
PMID: 31832205
Activation of MrgX2, an orphan G protein-coupled receptor expressed on mast cells, leads to degranulation and histamine release. Human MrgX2 binds promiscuously to structurally diverse peptides and small molecules that...
10.
Bargh J, Isidro-Llobet A, Parker J, Spring D
Chem Soc Rev
. 2019 Jul;
48(16):4361-4374.
PMID: 31294429
Antibody-Drug Conjugates (ADCs) are now established as a major class of therapeutics for the clinical treatment of cancer. The properties of the linker between the antibody and the payload are...